Insider · CIK 0001111620
Richard J Berman
Files at BIVI (BIOVIE INC.), CELU (Celularity Inc). First filing -, latest -.
In brief
Richard J Berman files SEC Form 4 as director at BIVI (BIOVIE INC.), and also at CELU (Celularity Inc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Richard J Berman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 20, 2024 | BIVI BIOVIE INC. | AGrant or award Common Stock | +34,200 | $0.00 | $0 | 40,643 | Jan 7, 2025 |
| Dec 20, 2024 | BIVI BIOVIE INC. | AGrant or award Stock Option (right to buy)derivative | +23,155 | $0.00 | $0 | 23,155 | Jan 7, 2025 |
| Dec 19, 2024 | CELU Celularity Inc | AGrant or award Class A Common Stock | +67,416 | $0.00 | $0 | 67,416 | Jan 6, 2025 |
| Dec 19, 2024 | CELU Celularity Inc | AGrant or award Stock Option (Right to Buy)derivative | +84,746 | $0.00 | $0 | 202,857 | Jan 6, 2025 |
Questions about Richard J Berman
Answered from the filings on this page, as of the latest one.
Is Richard J Berman buying or selling?
Richard J Berman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Richard J Berman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Richard J Berman has 0.
Where does Richard J Berman file Form 4?
Richard J Berman has filed Form 4 at BIVI (BIOVIE INC.); CELU (Celularity Inc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.